Company: DMAC
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001437749-25-026207
Chunk: 0

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Item 1
Chunk 0
---
 financial statements.
 
   2

  

DiaMedica Therapeutics Inc.
 Condensed Consolidated Statements of Operations and Comprehensive Loss
 (In thousands, except share and per share amounts)
 (Unaudited)
 
 
                                                                          Three Months Ended June 30,                                    Six Months Ended June 30,                 
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                          2025                           2024                           2025                           2024                        
Operating expenses:                                                                                                                                                                
Research and development                                      $5,822                            $3,928                      $11,478                           $7,604               
General and administrative                                                2,185                             1,710                       4,673                             3,775    
Operating loss                                                           (8,007   )                        (5,638   )                 (16,151   )                       (11,379   )
Other income, net                                             314                               526                         757                                           1,123    
Loss before income tax expense                                           (7,693   )                        (5,112   )                 (15,394   )                       (10,256   )
Income tax expense                                                           (6   )                            (7   )                     (12   )                           (14   )
Net loss                                                                 (7,699   )                        (5,119   )                 (15,406   )                       (10,270   )
Other comprehensive loss                                                                                                                                                           
Unrealized loss on marketable securities                                    (19   )                           (12   )                     (37   )                           (57   )
Net loss and comprehensive loss                               $(7,718             )             $(5,131             )       $(15,443            )             $(10,327            )
Basic and diluted net loss per share                          $(0.18              )             $(0.13              )       $(0.36              )             $(0.27              )
Weighted average shares outstanding – basic and diluted              42,957,619                        38,068,378                  42,901,093                        38,013,189    

See accompanying notes to the condensed consolidated financial statements.
 
   3

  

DiaMedica Therapeutics Inc.
 Condensed Consolidated Statements of Shareholders’ Equity
 For the Three Months Ended June 30, 2025 and 2024
 (In thousands, except share amounts)
 (Unaudited)
 
 
                                                                                           Common          Paid-In      Accumulated Other         Accumulated              Total         
                                                                                           Shares          Capital        Comprehensive             Deficit            Shareholders’     
                                                                                                                          Income (Loss)